PLANNING COMMITTEE

Dr. Wendy Lam, B Sc. (Pharm), MD, FRCPC

Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Burnaby, BC

Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.

She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.

She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.

Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.

She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association

Dr. Laurie H. Sehn, MD, MPH

Clinical Professor
Centre for Lymphoid Cancer,
British Columbia Cancer Agency and
University of British Columbia,
Vancouver, BC

Dr. Laurie Sehn is currently Clinical Professor with the British Columbia Cancer Agency and University of British Columbia, Canada. She has been a medical oncologist and clinical investigator at the BC Cancer Agency since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr. Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA. She was trained in Haematology-Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard University, Boston, and received a Masters of Public Health degree from Harvard School of Public Health, Harvard University. Prior to returning to Canada, she spent a year at the Dana-Farber Cancer Institute attending on the Bone Marrow Transplant service. Dr. Sehn is Chair of the medical advisory board for the International Lymphoma Coalition. She has also served as a member of the editorial board of Journal of Clinical Oncology and Leukemia Lymphoma, and is currently an Associate Editor for Blood. Dr. Sehn also serves as co-chair of the Lymphoma Site of the Canadian Cancer Trials Group.

Dr. Douglas A. Stewart, BMSc, MD, FRCP(C)

Professor, Departments of Oncology and Medicine,
University of Calgary and Tom Baker Cancer Centre
Calgary, AB

Dr. Doug Stewart obtained his medical degree from the University of Alberta in 1987, completed Internal Medicine and Medical Oncology Residencies at the University of Ottawa, and then a Fellowship in Bone Marrow Transplantation and Lymphoma Management at the University of Nebraska Medical Center in Omaha.  Since July 1994, he has been practicing Medical Oncology at the Tom Baker Cancer Centre in Calgary where he is a member of the Hematology and Breast Tumor Groups as well as the Blood and Marrow Transplant Program. Dr. Stewart is Professor in the Departments of Oncology and Medicine at the University of Calgary. His clinical research activities involve lymphoma and hematopoietic stem cell transplantation.

Dr. Pamela Skrabek, MD, MSc, FRCPC

Chair Lymphoproliferative Disease Site Group
Hematologist at CancerCare Manitoba
Winnipeg Manitoba

Dr. Pamela Skrabek is hematologist who completed medical school and residencies in Internal Medicine and Haematology at the University of Manitoba. Subsequently she received a Manitoba Health Research Council Clinical Research Fellowship award and completed additional training in lymphoma. She has completing a Master of Science in Community Health Sciences with a thesis project examining patient and system factors resulting in delays in diagnosis and treatment of lymphoma. As chair of the provincial Lymphoproliferative Disease Site Group (DSG) she provides leadership and coordination for DSG multidisciplinary clinics, teaching and educational, administrative and research activities. She is also site Medical Director of Buhler Cancer Centre at Victoria General Hospital.

Dr. Christine Chen, MD, FRCPC

Director Autologous Stem Cell Transplant Program
Princess Margaret Cancer Centre
Toronto, ON

Christine Chen is an Associate professor at the University of Toronto (U of T) and Head of the Autologous Stem Cell Transplant program at the Princess Margaret Cancer Centre, University Health Network (UHN), in Toronto, Canada. Dr. Chen is a member of the clinical research group for multiple myeloma and related mature B-cell disorders, including chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM). Princess Margaret Cancer Centre is the largest tertiary care center for cancer in Canada, performing over 260 stem cell transplants per year and seeing over 350 new referrals for myeloma, CLL and WM. Dr. Chen is a clinical investigator with research interests focusing on the development of novel approaches for these disorders. Dr. Chen underwent her internal medicine training at the University of British Columbia in Vancouver and hematology residency training at McMaster University in Hamilton. Upon completing a transplant clinical research fellowship at Princess Margaret Cancer Centre, she joined the faculty of the Department of Medical Oncology and Hematology at the U of T and subsequently obtained her Masters in Education from the Ontario Institute of Studies in Education (U of T). She therefore also takes an active role in medical education and acted as the U of T Hematology Training Program Director from 2003-2008 and is the current education coordinator for the myeloma group.

Dr. Michael Crump, MD, FRCPC

Cancer Clinical Research Unit (CCRU)
Princess Margaret Cancer Centre
Toronto, ON

Research Interests
Clinical and translational research in lymphoma, with a focus on stem cell transplantation and development of novel therapies, as well as late effects of treatment. Applied molecular oncology

Additional Appointments and Professional Affiliations
Cancer Clinical Research Unit Member, Princess Margaret.
National Cancer Institute – US Lymphoma Steering Committee Member.
National Cancer Institute – US Hodgkin’s Lymphoma Working Group Member.
Chair, National Cancer Institute of Canada – Clinical Trials Group Lymphoma Committee.
Co-Chair, National Cancer Institute of Canada – Clinical Trials Group Hematology Disease Site.
National Cancer Institute of Canada – Clinical Trials Group Investigational New Drug Programme Executive Committee Member.
National Cancer Institute of Canada – Clinical Trials Group Hematology Executive Committee Member.
Consultant, Ontario Ministry of Health and Long-term Care Committee to Evaluate Drugs (CED), Oncology Sub-Committee.
Cancer Care Ontario, Hematology Disease Site Practice Guideline Committee Member.
Cancer Care Ontario, Stem Cell Transplant Steering Committee Member.

Dr. Chaim Shustik, MD, FRCPC

Professor of Medicine, McGill University,
Montreal, QC

Chaim Shustik is Professor of Medicine at McGill University.

He obtained a medical degree at the University of Toronto and completed a haematology fellowship at Tufts-New England Medical Center.

He is on staff at the Royal Victoria Hospital in Montreal and has been involved in clinical trials in multiple myeloma and other hematologic malignancies

Dr. Stephen Couban, MD

Head/Division of Hematology
QEII Health Sciences Centre
Halifax, NS

Dr. Couban received a Bachelor of Science degree from McGill University in 1982 and his M.D. from Dalhousie University in 1986. He completed a residency in Internal Medicine at Dalhousie University in Halifax and went on to complete a fellowship in Hematology at McMaster University in Hamilton. He also undertook two years of specialty training in bone marrow transplantation at the Princess Margaret Hospital in Toronto as a National Cancer Institute of Canada Terry Fox Research Fellow.

In 1997, Stephen Couban joined the Department of Medicine at Dalhousie University and the Capital District Health Authority in Halifax, Nova Scotia. He is Service Chief and Interim Head of the Division of Hematology and Director of the Blood and Marrow Transplant Program. His research interests have focused on allografting and in particular on exploration of different types of grafts including G-CSF stimulated allogeneic peripheral blood allografts and G-CSF stimulated bone marrow allografts. Stephen Couban is currently President of the Canadian Hematology Society, Past-President of the Canadian Blood and Marrow Transplant Group and Co-Chair of the Hematology Site Group of the National Cancer Institute of Canada Clinical Trials Groups.

PLANNING COMMITTEE / ALLIED HEALTH SESSIONS

Nanette Cox-Kennett, BsCN, MN, NP

Cross Cancer Institute
Edmonton, AB

Nan has been working in oncology for longer than she cares to remember. She has previously been a staff nurse, patient educator, staff educator and since 2005 as Nurse Practitioner for the Hematology and Bone Marrow Transplant Program at the Cross Cancer Institute. Primary interests are: CLL, stem cell collection and cardio-oncology survivorship concerns post transplant.

Nikki Blosser, BSc. Pharm, ACPR

Clinical Pharmacist, Blood and Marrow Transplant Clinic
Tom Baker Cancer Centre

Nikki graduated from Memorial University of Newfoundland School of Pharmacy in 2010 and then moved to Calgary to complete an Accredited Canadian Residency Program with a focus in oncology. For the past six years she has been working as a clinical pharmacist in the Blood and Marrow Transplant Program at the Tom Baker Cancer Centre. Nikki continues to precept Cancer Care pharmacy residents in their BMT rotations. She obtained her Advanced Prescribing Authority (APA) in 2013 and helped implement the pharmacist-led therapeutic drug monitoring role in the BMT clinic.

Michelle Forman, RN, CON(C)

Burnaby Cancer Centre
Burnaby, BC

Michelle has been nursing for 26 years, and has spent her entire career working at Burnaby Hospital, B.C. Michelle worked in a variety of settings, including acute medicine, discharge planning, and IV therapy, before settling in to the outpatient Oncology Clinic in 1995.

The community clinic is comprised of two hematologist oncologists and one medical oncologist, as well as a dedicated team of allied health professionals who treat a wide variety of patients and tumor types. Michelle is actively involved in staff education, patient teaching, chemotherapy administration, clinical trials, as well as symptom and side effect management.

Michelle is passionate about oncology nursing and feels that her knowledge and experience play an integral role in helping to provide for the physical and emotional patient care needs. Michelle has also enjoyed the opportunity to be involved in many initiatives aimed at enhancing the cancer patients experience as well as the educational needs of fellow oncology health care professionals.

She is also a founding member and ongoing member of the organizing committee for the NACCC conference, an annual provincial conference in Oncology Nursing.